Not all cancer genetic tests are equal — clinical NGS panels and consumer array tests offer radically different coverage. Here is the complete 2026 comparison.
By Dr. Elena Marsh, Health Technology Correspondent
Published: November 18, 2026 · 10 min read
Clinical-grade hereditary cancer panels (Myriad MyRisk 48 genes, Invitae 84 genes, Color 30 genes) use full NGS sequencing in CLIA-certified labs and are clinically equivalent to hospital testing. Consumer tests (23andMe) cover only 3 BRCA variants, missing 97%+ of clinically significant BRCA mutations. For actionable hereditary cancer risk information, clinical-grade testing is essential. Consumer tests are not adequate substitutes for clinical BRCA screening.
The at-home cancer genetic testing market divides into two fundamentally different categories that are often conflated in consumer comparisons. Clinical-grade hereditary cancer tests use next-generation sequencing (NGS) — the same technology used in hospital genetic laboratories — to read and analyse the full sequence of relevant cancer-associated genes. Consumer array-based tests use genotyping chips that only check for specific, predetermined variants chosen during chip design.
This distinction has profound clinical implications. BRCA1 alone has over 1,800 pathogenic variants documented in clinical databases. 23andMe's health test covers three of them — the three Ashkenazi Jewish founder variants that are prevalent in one specific population. A negative result from 23andMe's BRCA test means those three specific variants were not found. It says nothing about the other 1,797+ pathogenic BRCA1 variants, nor anything about BRCA2, nor any of the other 20+ clinically actionable hereditary cancer genes.
| Test | Technology | Genes covered | CLIA certified | Price |
|---|---|---|---|---|
| Myriad MyRisk | NGS + Sanger confirm | 48 genes | Yes (CAP) | $250 w/ ins; ~$4,000 self-pay |
| Invitae (84 gene) | NGS | 84 genes | Yes (CAP) | $250 self-pay |
| Color Genomics | NGS | 30 genes | Yes (CAP) | $249–$299 direct |
| Ambry Genetics | NGS + MLPA | 42+ genes | Yes (CAP) | $250 w/ ins |
| 23andMe Health | Genotyping array | 3 BRCA variants only | Yes (limited) | $229 (full kit) |
The clinical significance of a hereditary cancer panel is determined primarily by the number of clinically actionable genes it covers — genes for which a positive result changes medical management. The core actionable genes in 2026 guidelines include:
A clinical-grade 48–84 gene panel covers all of these plus moderate-penetrance genes (CHEK2, RAD51C/D, BARD1) where risk estimates are still being refined. Consumer tests with limited variant coverage miss the majority of clinically significant findings across all these genes.
Deep Dive
Our comprehensive guide covers the science, protocols, and tools in detail — with FAQs answered by our research team.
Read the Full Guide →© 2026 QuanMed - All rights reserved